Menu ausklappen


Sarcomas are a rare type of cancer than can either originate from soft tissue (for instance connective tissue, muscle tissue, fat tissue, or blood vessels) or from supporting tissue (bones and cartilage). According to the World Health Organization’s (WHO) current classification, there are roughly 100 different types of sarcomas. They differ in terms of origin, microscopic appearance, molecular genetic changes, and their biological behavior. Prognosis, choice of treatment, and the success thereof depend on awareness of these differences. The best guarantee for a successful treatment is therefore a precise characterization of the tumor. Personalized therapy is becoming more prominent in this area, but even for targeted therapies, the success rates vary. By undertaking molecular testing, the success rate can however be reliably predicted. This allows preventing useless therapies, unnecessary procedures and avoidable side effects.

More than 20.000 genomes determine the tumor-biological behavior (growth rate, aggression, metastasis, response to treatment) of any given tumor, yet only a few find consideration in conventional cancer treatment.

While you can see less than 20% of an iceberg above the water line, the discernable amount of treatment-relevant tumor genes ranges only in the part-per-thousands.

New Methods of Analysis Characterize the Tumor

The PANTHER-test makes an important contribution to personalized tumor treatment as it provides an extensive analysis of gene activity patterns. The 3D spheroid chemosensitivity test moves away from the trial and error principle of conventional cytotoxic treatment. Cytotoxic treatment offers uncertain prospects of success while severely limiting a patient’s quality of life. Thanks to new developments in molecular genetics and bio-medicine, targeted therapies are moving increasingly into the center of medical interest. Targeted therapies focus on a tumor’s individual characteristic mutations or on the increased activity of cancer genes on a molecular level. Innovative procedures such as the PANTHER-test in connection with the MultiOncogen Mutation tests (MOMs), which undertake a comprehensive mutation analysis of the most important cancer and tumor suppression genes, decipher the characteristics of individual cancer genes that offer the key to targeted therapies. Such combinable CancerGenomeLandscape assays are available in different variations according to the problem at hand.

Chemo-/Biopharmaceutical Sensitivity (DCBS) based on 3D-spheroid technology


Gentle Cancer Treatment via Personalization

The innovations in developing individual vaccines are bringing the dream of personalized, highly specific and gentle cancer therapy closer to realization. New diagnostic tools, pan-genomic PANTHER gene activity testing and EXOM-MOMs make a significant contribution to the development of individual cancer vaccines.

With regard to the production of such vaccines in particular, it can be of critical importance to cryopreserve part of the tumor tissue after an operation. Uomorphis[LvC1]  offers such cryopreservation, either as standard preservation frozen in the gas phase of liquid nitrogen at a temperature of under -190°C or as LIFE-cryopreservation, in which the tumor cells are isolated and frozen alive in a computer-controlled specialized medium.

To determine the best and most promising course of action in your case, you are very welcome to contact Prof. Bojar for a personal consultation.

We are happy to consult you in finding the right treatment for Lung Cancer!

Testing Methods for Sarcomas

Chemo-/Biopharmaceutical Sensitivity

Using isolated, living tumor cells, this test determines the response to cytotoxic and biopharmaceutical treatments.


This molecular-genetic test serves to determine the risk of metastasis of both lymph node positive and lymph node negative primary breast cancer. It can thus be used to decide for or against adjuvant chemotherapy.

MultiOncogen Mutation Tests (MOMs)

MultiOncogen Mutation tests are several, comprehensive mutational tests. When tailored to a specific tumor disease, MOMs identify the mutations relevant to target therapies.


The most comprehensive of the molecular-genetic tests determines the activity of all of a tumor’s genes. It thus allows evaluating the risk of primary breast cancer (OncoAssay Score) and the response to several possible courses of treatment. Suitable for all kinds of tumors.

upa PAI 1

Proteases (uPA/PAI-1)

The test is used to assess the risk of further growth of lymph node negative primary breast cancer. As such, it can be used to help make a decision for or against adjuvant chemotherapy.

zirkulierende Tumor DNA

Circulating Tumor DNA

The test identifies mutations in a tumor’s DNA via serum or plasma. It is used within the real-time mutation analysis in several tumor diseases under targeted therapy (real-time liquid biopsy). It allows for a timely discovery of a tumor’s growing resistance to the targeted therapy.

CTC circulating tumor cells

Circulating Tumor Cells (CTC)

The test serves to determine how the blood is affected by tumor cells. It allows for a molecular-genetic characterization of the tumor disease (real-time liquid biopsy).

NextGen Oncology Group

NextGen Oncology Group